160 related articles for article (PubMed ID: 35438133)
1. Construction of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in thymic epithelial tumors.
Su Y; Ou Y; Chen Y; Ma X
Biosci Rep; 2022 May; 42(5):. PubMed ID: 35438133
[TBL] [Abstract][Full Text] [Related]
2. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
3. lncRNAs classifier to accurately predict the recurrence of thymic epithelial tumors.
Su Y; Chen Y; Tian Z; Lu C; Chen L; Ma X
Thorac Cancer; 2020 Jul; 11(7):1773-1783. PubMed ID: 32374079
[TBL] [Abstract][Full Text] [Related]
4. Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence.
Liu W; Yang HS; Zheng SY; Weng JH; Luo HH; Lei YY; Feng YF
BMC Genomics; 2022 Sep; 23(1):656. PubMed ID: 36114454
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Value of Tumor Mutation Burden and Immune Cell Infiltration in Thymic Epithelial Tumors.
Du H; Xie S; Guo W; Zhang W; Che J; Zhu L; Hang J
Ann Clin Lab Sci; 2021 Jan; 51(1):44-54. PubMed ID: 33653780
[TBL] [Abstract][Full Text] [Related]
6. Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors.
Wang ZM; Xu QR; Kaul D; Ismail M; Badakhshi H
Thorac Cancer; 2021 Jul; 12(13):1995-2006. PubMed ID: 34033229
[TBL] [Abstract][Full Text] [Related]
7. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
Zhang L; Li L; Zhan Y; Wang J; Zhu Z; Zhang X
Front Oncol; 2020; 10():542140. PubMed ID: 33552945
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature.
Lai J; Chen B; Zhang G; Li X; Mok H; Liao N
J Transl Med; 2020 Nov; 18(1):416. PubMed ID: 33160384
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors.
Li S; Yuan Y; Xiao H; Dai J; Ye Y; Zhang Q; Zhang Z; Jiang Y; Luo J; Hu J; Chen C; Wang G
Clin Epigenetics; 2019 Mar; 11(1):38. PubMed ID: 30832724
[TBL] [Abstract][Full Text] [Related]
11. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
13. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
14. Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
Umemura S; Chen V; Chahine JJ; Kallakury B; Zhao X; Lee H; Avantaggiati ML; He Y; Wang C; Giaccone G
Clin Lung Cancer; 2022 Mar; 23(2):e140-e147. PubMed ID: 34393062
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
Yamamoto Y; Iwahori K; Funaki S; Matsumoto M; Hirata M; Yoshida T; Kanzaki R; Kanou T; Ose N; Minami M; Sato E; Kumanogoh A; Shintani Y; Okumura M; Wada H
Sci Rep; 2020 Mar; 10(1):4064. PubMed ID: 32132638
[TBL] [Abstract][Full Text] [Related]
16. LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism.
Tito C; Ganci F; Sacconi A; Masciarelli S; Fontemaggi G; Pulito C; Gallo E; Laquintana V; Iaiza A; De Angelis L; Benedetti A; Cacciotti J; Miglietta S; Bellenghi M; Carè A; Fatica A; Diso D; Anile M; Petrozza V; Facciolo F; Alessandrini G; Pescarmona E; Venuta F; Marino M; Blandino G; Fazi F
Cell Death Dis; 2020 Nov; 11(11):959. PubMed ID: 33161413
[TBL] [Abstract][Full Text] [Related]
17. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
19. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
20. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
